Fairmount Funds Management as of March 31, 2026
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 12 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Damora Therapeutics Com New (DMRA) | 16.3 | $226M | 8.7M | 25.90 | |
| Dianthus Therapeutics (DNTH) | 15.4 | $213M | 2.5M | 83.92 | |
| Cogent Biosciences (COGT) | 15.3 | $212M | 5.5M | 38.49 | |
| Spyre Therapeutics Com New (SYRE) | 14.6 | $203M | 4.0M | 50.44 | |
| Oruka Therapeutics (ORKA) | 13.1 | $182M | 3.7M | 49.05 | |
| Miragen Therapeutics (VRDN) | 5.5 | $77M | 3.9M | 19.56 | |
| Enliven Therapeutics (ELVN) | 5.3 | $73M | 1.9M | 39.20 | |
| Jade Biosciences Com New (JBIO) | 4.6 | $64M | 4.6M | 14.05 | |
| Crescent Biopharma (CBIO) | 3.6 | $51M | 2.7M | 18.37 | |
| Zenas Biopharma (ZBIO) | 3.3 | $46M | 2.4M | 19.55 | |
| Apogee Therapeutics (APGE) | 1.8 | $25M | 299k | 84.17 | |
| Inhibikase Therapeutics Com New (IKT) | 1.0 | $15M | 8.6M | 1.68 |
